Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis

被引:26
作者
Iavarone, Massimo [1 ]
Manini, Matteo Angelo [1 ]
Sangiovanni, Angelo [1 ]
Fraquelli, Mirella [2 ]
Forzenigo, Laura Virginia [3 ]
Di Tommaso, Luca [4 ]
Aghemo, Alessio [1 ]
Roncalli, Massimo [4 ]
Ronchi, Guido [1 ]
Colombo, Massimo [1 ]
机构
[1] Univ Milan, Div Gastroenterol 1, Ctr AM & A Migliavacca Liver Dis, Fdn IRCCS Ca Granda Maggiore Hosp, I-20122 Milan, Italy
[2] Univ Milan, Div Gastroenterol 2, Fdn IRCCS Ca Granda Maggiore Hosp, I-20122 Milan, Italy
[3] Univ Milan, Div Radiol, Fdn IRCCS Ca Granda Maggiore Hosp, I-20122 Milan, Italy
[4] Ist Clin Humanitas, Dept Pathol, Milan, Italy
关键词
Cirrhosis; CT-scan; Hepatocellular carcinoma; Liver cell dysplasia; Ultrasound; EARLY HEPATOCELLULAR-CARCINOMA; MANAGEMENT; LESIONS; HEPATITIS; IMPACT; HSP70;
D O I
10.1016/j.dld.2012.08.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Dysplastic nodules in cirrhosis herald a very high risk of transition to hepatocellular carcinoma. A better understanding of the relationships between dysplastic nodules and hepatocellular carcinoma development may help refining strategies of enhanced follow-up. Methods: All consecutive cirrhotics with a histologically proven de novo dysplastic nodule, were retrospectively identified and underwent alternating abdominal ultrasound and contrast-computed tomography every 3 months. An ultrasound-guided liver biopsy was the diagnostic gold standard, whereas surveillance and recall policies were according to current guidelines. Results: Among 36 patients with dysplastic nodule (21 low-grade, 15 high-grade, 17.4 +/- 2.6 mm), 17 (47%) showed arterial wash-in, 15 (42%) portal/venous hypodensity whereas 4 (11%) had neither pattern. During 6-128 (median 36) months, 21 patients developed a hepatocellular carcinoma at a rate of 13.8% per year, intranodular = 8.7% vs extranodular = 7.1% per year. Hepatocellular carcinoma occurred more frequently in high-grade than low-grade dysplastic nodules (32.2% vs 9.3% per year, p = 0.0039); the maximum time to hepatocellular carcinoma transformation was 27 months for intranodular vs 67 months for extranodular tumours (p = 0.025). No contrast-computed tomography pattern predicted neoplastic transformation of dysplastic nodules. Conclusion: The histological examination of liver nodules in cirrhosis lacking the imaging hallmark of hepatocellular carcinoma improves both prognostication and outcome of surveillance, since it dictates the intensity of the radiological follow-up. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 33 条
[1]   Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009) [J].
Arii, Shigeki ;
Sata, Michio ;
Sakamoto, Michiie ;
Shimada, Mitsuo ;
Kumada, Takashi ;
Shiina, Shuichiro ;
Yamashita, Tatsuya ;
Kokudo, Norihiro ;
Tanaka, Masatoshi ;
Takayama, Tadatoshi ;
Kudo, Masatoshi .
HEPATOLOGY RESEARCH, 2010, 40 (07) :667-685
[2]   Natural history of compensated viral cirrhosis:: a prospective study on the incidence and hierarchy of major complications [J].
Benvegnù, L ;
Gios, M ;
Boccato, S ;
Alberti, A .
GUT, 2004, 53 (05) :744-749
[3]   Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma [J].
Bolondi, L ;
Gaiani, S ;
Celli, N ;
Goffieri, R ;
Grigioni, WF ;
Leoni, S ;
Venturi, AM ;
Piscaglia, F .
HEPATOLOGY, 2005, 42 (01) :27-34
[4]   Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development [J].
Borzio, M ;
Fargion, S ;
Borzio, F ;
Fracanzani, AL ;
Croce, AM ;
Stroffolini, T ;
Oldani, S ;
Cotichini, R ;
Roncalli, M .
JOURNAL OF HEPATOLOGY, 2003, 39 (02) :208-214
[5]  
Borzio M, 2010, HEPATOLOGY, V52, p1162A
[6]   Primary liver cancer:: Worldwide incidence and trends [J].
Bosch, FX ;
Ribes, J ;
Díaz, M ;
Cléries, R .
GASTROENTEROLOGY, 2004, 127 (05) :S5-S16
[7]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[8]   Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[9]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[10]   Characterization of liver lesions by real-time contrast-enhanced ultrasonography [J].
Celli, Natascia ;
Gaiani, Stefano ;
Piscaglia, Fabio ;
Zironi, Gianni ;
Camaggi, Valerla ;
Leoni, Simona ;
Righini, Roberto ;
Bolondi, Luigi .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2007, 19 (01) :3-14